창부도담탕이 비만 유도 흰쥐에 미치는 영향
Effects of Changbudodam-tang on Obesity-induced Rats
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives: This study was designed to evaluate the efficacy of Changbudodam-tang on obesity by using high-fat diet rats. Methods: Rats were divided into five groups. Normal group: Normal diet, Control group: High-fat diet, Positive control group: High-fat diet+Dietamin 4 mg/kg/day, Changbudodam-tang-Low group: High-fat diet+Changbudodam-tang 250 mg/kg/day, Changbudodam-tang-High group: High-fat diet+Changbudodam-tang 500 mg/kg/day. Weight, food intake were measured every week. After 7 weeks, total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, Triglyceride, free fatty acid, aspartate aminotransferase, alanine aminotransferase, complete blood count were measured and messenger ribonucleic acid expression of adiponectin, peroxisome proliferator-activated receptor-γ, leptin were observed using Reverse transcription polymerase chain reaction of liver cells. Results: There was no difference in food intake between groups. Body weight tended to decrease compared with the Control group, but it wasn’t statistically meaningfull. The total cholesterol, low density lipoprotein-cholesterol, Triglyceride, free fatty acid tended to decrease compared with the Control group. High density lipoprotein-cholesterol tended to decrease compared with the Control group, but it wasn’t statistically meaningfull. White blood cell, red blood cell, hemoglobin, platelet, aspartate aminotransferase, alanine aminotransferase were not affected by Changbudodam-tang. The messenger ribonucleic acid expression of Adiponectin, peroxisome proliferator- activated receptor-γ, leptin, which are involved in the differentiation of adipocytes, was decreased compared with the Control group. Conclusions: Based on the results above, it is suggested that Changbudodam-tang can be applied to improving serum lipid levels in obese patients caused by high fat diets.
Abstract
Objectives: This study was designed to evaluate the efficacy of Changbudodam-tang on obesity by using high-fat diet rats. Methods: Rats were divided into five groups. Normal group: Normal diet, Control group: High-fat diet, Positive control group: High-fat diet+Dietamin 4 mg/kg/day, Changbudodam-tang-Low group: High-fat diet+Changbudodam-tang 250 mg/kg/day, Changbudodam-tang-High group: High-fat diet+Changbudodam-tang 500 mg/kg/day. Weight, food intake were measured every week. After 7 weeks, total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, Triglyceride, free fatty acid, aspartate aminotransferase, alanine aminotransferase, complete blood count were measured and messenger ribonucleic acid expression of adiponectin, peroxisome proliferator-activated receptor-γ, leptin were observed using Reverse transcription polymerase chain reaction of liver cells. Results: There was no difference in food intake between groups. Body weight tended to decrease compared with the Control group, but it wasn’t statistically meaningfull. The total cholesterol, low density lipoprotein-cholesterol, Triglyceride, free fatty acid tended to decrease compared with the Control group. High density lipoprotein-cholesterol tended to decrease compared with the Control group, but it wasn’t statistically meaningfull. White blood cell, red blood cell, hemoglobin, platelet, aspartate aminotransferase, alanine aminotransferase were not affected by Changbudodam-tang. The messenger ribonucleic acid expression of Adiponectin, peroxisome proliferator- activated receptor-γ, leptin, which are involved in the differentiation of adipocytes, was decreased compared with the Control group. Conclusions: Based on the results above, it is suggested that Changbudodam-tang can be applied to improving serum lipid levels in obese patients caused by high fat diets.
참고문헌 (36)
- The Society of Korean Medicine Obstetrics & Gynecology, "Oriental Obstetrics &Gynecology (Vol 2)", pp.295~ (2012), Euiseongdang
- Hong EK, "Pathophysiology of Adult Obesity and Related-disease", Korean Clinical Diabetes, 9(3), pp.148~152 (2008)
- Sullivan PW, "The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States", Qual Life Res, 17(8), pp.1063~1071 (2008)
- "Korean National Health and Nutrition Survey"[URL]
- "11.4679 trillion won in social losses from obesity"[URL]
- Kim CH, "Pharmacologic Therapy for Obesity", Diabetes and Metabolism Journal, 9(3), pp.173~177 (2008)
- Connolly HM, "Valvular heart disease associated with fenfluraminephentermine", N Engl J Med, 337(9), pp.581~588 (1997)
- James WP, "Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects", N Engl J Med, 363(10), pp.905~922 (2010)
- Chae IS, "Sinpyeon Jeoncheongjunamyeokwa Seopcheonsayeokwa", pp.192~193 (1992), Daeseong
- Hwang DY, "Jeungmaek Bangyakhappyeon Jeungbobang", pp.330~331 (1996), Namsandang
- 양승정, "蒼附導痰湯이 estradiol valerate로 유발된 백서의 다낭성 난소에 미치는 影響", 대한한방부인과학회지, 15(2), pp.1~11 (2002), 대한한방부인과학회
- Song JM, "Experimental Study for the Effect of Cheonghaechangsa-hwan and Changbudodam-hwan", J Korean Obstet Gynecol, 10(1), pp.151~161 (1997)
- Kang BH, "Effects of Changbudodam -hwan on the ovulation in rats", The Journal of Traditional Korean Medicine, 13(1), pp.15~26 (2003)
- Korean Society For The Study Of Obesity, "Clinical obesity", pp.19~29 (2001), Korea Medical Book Publishing Company
- 대한내분비학회, "비만치료지침 2010 권고안", Endocrinology and Metabolism, 25(4), pp.301~304 (2010), 대한내분비학회
- "Heavy Burden of Obesity: The Economics of Prevention"[URL]
- Lee HK, "Obesity and Its Associated Diseases", Journal of Obesity & Metabolic Syndrome, 1(1), pp.34~39 (1992)
- Hensrud DD, "Pharmacotherapy for obesity", Med Clin North Am, 84(2), pp.463~476 (2000)
- 김미경, "2014 Clinical Practice Guidelines for Overweight and Obesity in Korea", Endocrinology and Metabolism, 29(4), pp.405~409 (2014), 대한내분비학회
- Vetter ML, "Behavioral and pharmacologic therapies for obesity", Nat Rev Endocrinol, 6(10), pp.578~588 (2010)
- 서미혜, "2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 28(1), pp.40~45 (2019), 대한비만학회[DOI]
- Shin HJ, "Domestic adverse event and signal detection of anti-obesity medicines using KIDS-KD. Department of Pharmacy", Department of Pharmacy, pp.2020
- "Medication Details" (2020)[URL]
- 이철진, "비만 치료의 최신 지견", Korean Journal of Health Promotion, 19(4), pp.171~185 (2019), 대한임상건강증진학회
- Kim DH, "Hwangjenaekyeongsomun", pp.652~ (2002), Euiseongdang
- The Society of Korean Medicine Rehabilitation, "Korean Rehabilitation Medicine" (2015), Koonja
- 정장원, "인체를 대상으로 한 한의학적 비만 연구의 최신 국내 동향분석", 한방재활의학과학회지, 26(1), pp.49~61 (2016), 한방재활의학과학회
- Sin MK, "Imsangbonchohak", pp.172~174 (2000), Samkwanginswaesa
- Ha KS, "Silyongbukwabangjehak", pp.272~273 (1997), Inminwisaengchulpansa
- Cnop M, "Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoprotein; evidence for independent roles of age and sex", Diabetologia, 46(4), pp.459~469 (2003)
- Weiss R, "Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation", J Clin Endocricnol Metab, 88(5), pp.2014~2022 (2003)
- Hotta K, "Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 deabetic patients", Arterioscler. Thromb Vasc Biol, 20(6), pp.1595~1604 (2000)
- Yang WS, "Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin", J ClinEndocrinol Metab, 86(8), pp.3815~3824 (2001)
- Rosen ED, "PPAR is required for differentiation of adipose tissue in vitro", Mol cell, 4(4), pp.611~617 (1999)
- Maffei M, "Leptin levels in human and rodent : Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects", Nat Med, 1(11), pp.1155~1216 (1995)
- Friedman JM, "Leptin and the regulation of body weight in mammals", Nature, 395(6704), pp.763~833 (1998)